Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19376 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Deevyashali Parekh und 30 weiteren Autor:innen. Beteiligte Einrichtung: Texas Children's Cancer Center, Texas Children's Hospital, Houston, Texas, USA. Hauptthemen laut MEDLINE: Clofarabine, Histiocytosis, Langerhans-Cell. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NIH HHS.
Abstract (Originalsprache)
Over 50% of patients with systemic LCH are not cured with front‐line therapies, and data to guide salvage options are limited. We describe 58 patients with LCH who were treated with clofarabine. Clofarabine monotherapy was active against LCH in this cohort, including heavily pretreated patients with a systemic objective response rate of 92.6%, higher in children (93.8%) than adults (83.3%). BRAF V600E+ variant allele frequency in peripheral blood is correlated with clinical responses. Prospective multicentre trials are warranted to determine optimal dosing, long‐term efficacy, late toxicities, relative cost and patient‐reported outcomes of clofarabine compared to alternative LCH salvage therapy strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Texas Children's Cancer Center, Texas Children's Hospital, Houston, Texas, USA.
- Department of Pediatrics, Division of Pediatric Hematology and Oncology, Baylor College of Medicine, Houston, Texas, USA.
- Department of Pediatrics, Weill Cornell Medical College, New York, New York, USA.
- Division of Pediatric Hematology/Oncology, C.S. Mott Children's Hospital, University of Michigan Medical School, Ann Arbor, Michigan, USA.
- Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
- Division of Hematology/Oncology/BMT, Central Michigan University College of Medicine, Children's Hospital of Michigan, Detroit, Michigan, USA.
ORCID-Profile: Olive S Eckstein, Nitya Gulati, Kenneth L McClain, Carl E Allen
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- NIH HHS
- National Institutes of Health
- St. Baldrick's Foundation
- Leukemia and Lymphoma Society
Zitieren
APA
Parekh, D., Lin, H., Batajoo, A., Peckham-Gregory, E., Karri, V., Stanton, W., Scull, B., Fleishmann, R., El-Mallawany, N., Eckstein, O. S., Prudowsky, Z. D., Gulati, N., Agrusa, J. E., Ahmed, A. Z., Chu, R., Dietz, M. S., Goldman, S. C., Hogarty, M. D., Imran, H., …, & Allen, C. E. (2024). Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis. British Journal of Haematology. https://doi.org/10.1111/bjh.19376
Vancouver
Parekh D, Lin H, Batajoo A, Peckham-Gregory E, Karri V, Stanton W, et al. Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis. British Journal of Haematology. 2024. doi:10.1111/bjh.19376
BibTeX
@article{Parekh2024,
author = {Parekh, Deevyashali and Lin, Howard and Batajoo, Akanksha and Peckham-Gregory, Erin and Karri, Vivekanudeep and Stanton, Whitney and Scull, Brooks and Fleishmann, Ryan and El-Mallawany, Nader and Eckstein, Olive S and Prudowsky, Zachary D and Gulati, Nitya and Agrusa, Jennifer E and Ahmed, Asra Z and Chu, Roland and Dietz, Matthew S and Goldman, Stanton C and Hogarty, Michael D and Imran, Hamayun and Intzes, Stefanos and Kim, Jenny M and Kopp, Lisa M and Levy, Carolyn Fein and Neff, Philip and Pillai, Pallavi M and Sisk, Bryan A and Schiff, Deborah E and Trobaugh-Lotrario, Angela D and Walkovich, Kelly and McClain, Kenneth L and Allen, Carl E},
title = {Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19376}
}
EUVIMED